HighYieldStocks Monday, 12/28/20 08:52:58 AM Re: None Post # of 290 GCAC is one of these top pick-and-shovel companies is the cannabis tech startup GCAC (Global Cannabis Applications Corp., USA: FUAPF, Canada: APP). The company just introduced the cannabis efficacy app Efixii App (which btw has potentially many other efficacy applications e.g. in the medical/pharma sector). For the first time, the efficacy and quality of cannabis products (mostly medical but also recreational) can be precisely measured now. The Efixii App was approved in record time and is available on both the Google Play Store and the Apple App Store. For each distributed gram, GCAC will earn CDN$0,38. Based on its newest Investor update from a few days ago, the company is planning to participate with its Efixii App and 36 growers in the distribution of 128 million grams by 2023. This will result in a high-profit margin revenue (65% EBITDA) of approx. CDN$48.6 Million. ( https://cdn-ceo-ca.s3.amazonaws.com/1fu8u5t-GCAC-IR_Dec23+v10.1.pdf ). Morningstar has an "undervalued" rating on GCAC (FUAPF/APP) and a fair-value price target of $0.20. Currently, shares of GCAC (FUAPF) trade just below $0.10 in the U.S. and at CDN$0.12 (APP) in Canada. Also due to its extremely low market cap of only approx. $15M, we think, IMO, that shares could rise to at least $0.50 to $1/share for an attractive basis and the company would be still valued at only a fraction of the initial Weedmaps/SSPK market cap. Long-term growth could be really astronomical with the company reaching a multi-billion dollar valuation. It can be expected that institutional investors will tap into the GCAC play (possibly perhaps via a buyout/merger) over time due to the phenomenal growth potential.